Rhythm Pharmaceuticals Inc(RYTM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.12 | Insider Own | 3.96% | Shs Outstand | 68.8M | Perf Week | 1.41% |
| Market Cap | 6.16B | Forward P/E | - | EPS next Y | 78.06% | Insider Trans | -9.92% | Shs Float | 66.1M | Perf Month | -9.31% |
| Enterprise Value | 6.05B | PEG | - | EPS next Q | -0.71 | Inst Own | 110.04% | Short Float | 16.28% | Perf Quarter | -17.19% |
| Income | -0.21B | P/S | 25.68 | EPS this Y | 5.28% | Inst Trans | 5.59% | Short Ratio | 16.06 | Perf Half Y | 5.01% |
| Sales | 0.24B | P/B | 59.79 | EPS next 5Y | - | ROA | -50.7% | Short Interest | 10.77M | Perf YTD | -16.41% |
| Book/sh | 1.5 | P/C | 18.62 | EPS past 3/5Y | 3.66% -0.46% | ROE | -199.95% | 52W High | -26.78% ($122.20) | Perf Year | -19.01% |
| Cash/sh | 4.81 | P/FCF | - | Sales past 3/5Y | 100.23% - | ROIC | -65.46% | 52W Low | 20.09% ($74.50) | Perf 3Y | 281.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -3.31% | Gross Margin | 88.91% | Volatility(W/M) | 3.36% 3.67% | Perf 5Y | 706.04% |
| Dividend TTM | - | EV/Sales | 25.23 | Sales Y/Y TTM | 53.51% | Oper. Margin | -83.62% | ATR (14) | 3.35 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.2 | EPS Q/Q | 2.55% | Profit Margin | -87.62% | RSI (14) | 42.05 | Recom | 1.2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.45 | Sales Q/Q | 46.91% | SMA20 | -0.77% ($90.16) | Beta | 2.18 | Target Price | $140.53 |
| Payout | - | Debt/Eq | 0.51 | Earnings | 2026/11/3 | SMA50 | -9.52% ($98.88) | Rel Volume | 0.43 | Prev Close | $89.27 |
| Employees | 414 | LT Debt/Eq | 0.44 | EPS/Sales Surpr. | 9.56% 5.32% | SMA200 | -8.12% ($97.38) | Avg Volume(3M) | 0.67M | Price | $89.47 |
| IPO | 2017/10/5 | Option/Short | Yes/Yes | Trades | 4691 | Volume | 289,466 | Change | 0.22% |
🧬 This is a commercial-stage biotech company that develops and sells therapies for rare hereditary obesity disorders. It generates revenue by selling treatments for rare obesity conditions caused by specific genetic mutations, and as a healthcare name, it is pursuing label expansions—such as for hypothalamic obesity—along with oral-formulation candidates. Value is driven by sales of its lead therapy and expansion into additional indications.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
Traded less than usual. That is 43% of its average volume.
Next earnings report: November 3
8 days to go.
RYTM has a sound balance sheet but weak earning power
Of every $100 in sales, $83.62 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,568. Peers typically go for $1,510.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +706.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 110.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #40 of 594 in the industry
Based on market cap of $6B.
IOVA#39 Iovance Biotherapeutics Inc $6B PER - RYTM#40 Rhythm Pharmaceuticals Inc $6B PER - 
LGND#41 Ligand Pharmaceuticals Inc $6B PER 33.0 
ORKA#42 Oruka Therapeutics Inc $6B PER - 
IMVT#43 Immunovant Inc $6B PER - 
FAQ
What kind of company is RYTM?
RYTM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RYTM?
The market cap of RYTM is approximately $6.2B, ranking 1,186 within its sector.
What is the 52-week high and low for RYTM?
RYTM has recorded a 52-week high of $122.20 and a low of $74.50.
